Ohio State Navbar

Ibrutinib Approved For CLL Treatment By FDA

The Food & Drug Administration has today announced approval of Ibrutinib for treatment of patients with Chronic Lymphocytic Leukemia who have recieved one prior therapy.


The CLL Experimental Therapeutics Laboratory would like to thank all of the patients that have contributed in our clinical and correlative research studies.  Without your support and participation, this would not have been possible.


We would also like to thank the Leukemia and Lymphoma Society, Four Winds Foundation, D. Warren Brown Foundation, Harry Mangurian Foundation, and Mr. and Mrs. Michael Thomas for their wonderful support of our research laboratory.